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Introduction
Head and neck squamous cell carcinoma 
(HNSCC) is a cancer that arises from the 
mucosal epithelium of the upper aerodigestive 
tract.1 Head and neck squamous cell carcinoma 
is an aggressive, life-threatening cancer 
associated with a high mortality rates. The 
incidence of HNSCC is about 90% of all head 
and neck cancers and is the sixth in the world. 
Head and neck squamous cell carcinoma is 
the seventh leading cause of death and is 
increasing in developing countries by about 
500,000 cases per year.2,3 The prevalence of 
head and neck cancer at Dr. Hasan Sadikin 
General Hospital Bandung for the 2010–2014 
period was 31.2%.4
Human papillomavirus (HPV) is one of the 
factors that cause the growth of abnormal 
cells. The HPV infection causes interactions 
between oncoprotein E6 and p53 in cell cycle 
control settings, apoptosis, and DNA repair. 
Disruption of TP53 leads to cancer proliferation 
and progression. The p53 and p73 proteins 
have similar domain structures, indicating 
analogous biological activity and contribute 
to the increased risk of HPV-16 in HNSCC. 
P53 instability leads to p21 transcription, 
deregulation of DNA repair, and inhibition 
of p53 proapoptotic function. Decreased 
p21, degradation of DNA deregulation, and 
inhibition of proapoptotic function may 
result in proliferation; whereas the decreased 
function of p53 proapoptosis can directly 
increase progressivity. Furthermore, the 
increased proliferation of epithelial cells with 
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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is an invasive neoplasm of epithelial 
tissue in the head and neck and one of the etiologies of HNSCC is human papillomavirus (HPV) which 
may be associated with the clinical stage of HNSCC. HPV infection in squamous cell epithelium produces 
specific IgG antibodies against HPV. IgG titer of HPV can help identify patients who are at risk for HPV-
related cancers. This study aimed to explore the association between IgG titer of HPV with the clinical 
stages of HNSCC. 
Methods: The design of this study was analytic cross sectional, conducted at the Outpatient Clinic of 
Otorhinolaryngology-Head and Neck Surgery, Division of Oncology, Dr. Hasan Sadikin General Hospital 
Bandung period September–December 2017. Patients with HNSCC were recruited, and history was 
taken. Furthermore, histopathologic examination and HPV IgG serology examination were performed 
using the ELISA method. The HPV IgG levels were compared by stage and data were analyzed using the 
Shapiro Wilks test and Unpaired T test.
Results: The HPV IgG was high in 75% (n=21) of HNSCC patients in the advanced stage and low in 25% 
(n=7) of patients in the early stage. There was a significant relationship between HPV IgG titer and early 
and advanced stage of  HNSCC (p=0.001).
Conclusions: The HPV IgG titer is related to the clinical stage of HNSCC indicating that the higher the 
HPV IgG level, the more advanced the clinical stage. Further study is needed to explore HPV IgG levels 
as a prognostic marker in HNSCC.
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high levels of HPV IgG causes progressivity of 
tumor.5
The increased risk of HNSCC is related to 
HPV-16 seropositivity examined using IgG 
ELISA. HPV-16 is also a risk factor associated 
with Oropharyngeal Squamous Cell Carcinoma 
(OPSCC). Moreover, HPV has also been linked 
to the pathogenesis of oral cancer. The 
death rate of head and neck squamous cell 
carcinoma is very high, associated with the 
stage of the tumor when patients first come 
to the hospital.6,7 This research was aimed to 
explore the correlation between IgG HPV titer 
and the clinical stage of HNSCC
 
Methods
This study was a cross-sectional analytic study 
at the Outpatient Clinic of Otorhinolaryngology-
Head and Neck Surgery, Division of Oncology, 
Dr. Hasan Sadikin General Hospital Bandung 
period September–December 2017. HNSCC 
patients were collected before recruitment. 
Informed consent was obtained from all 
individual participants included in the study.
Inclusion criteria were patients with head 
and neck tumors in the early and advanced 
stages with histopathological results of 
squamous cell carcinoma (SCC). Furthermore, 
HNSCC patients were included when they had 
not received radiation therapy, chemotherapy, 
or chemoirradiation. Exclusion criteria 
were patients with residual or recurrence 
of SCC, multiple carcinomas, patients who 
had received radiotherapy. The study was 
approved by the Research Ethics Committee of 
Dr. Hasan Sadikin Hospital Bandung, Indonesia 
No. LB.04.01/A05/EC/304/X/2017.
Clinical stages were designated by early-
stage (I-II) HNSCC, and advanced stage 
(III-IV) based on the 2017 American Joint 
Committee on Cancer (AJCC). The locations 
of HNSCC were the oropharynx, paranasal 
sinuses, nasopharynx, oral cavity, and larynx. 
Histopathology of SCC was classified based on 
the results of the biopsy showing squamous 
differentiation microscopically. The HPV IgG 
levels were obtained from blood serum and 
examined by ELISA method using monoclonal 
antibodies of with quantitative serum levels 
of 156–10.000 U/mL. Statistical analysis was 
performed using the Mann Whitney test and 
the Fisher’s Exact correlation test.
Results
In total, 28 patients with HNSCC were included, 
the most of patients were male (19 of 28) with 
a mean age of 53.78±8.385 years (range 33–
70 years). There was no relationship between 
gender (p=0.646) or age (p=0.972) with the 
clinical stage of HNSCC (Table 1).
Based on the location of the tumor, the most 
prevalent site was in the larynx (n=17) whereas 
advanced stage was the most prevalent site 
as shown in Table 2. Interestingly, there was 
a significant relationship between the HPV 
IgG levels and the clinical stage of HNSCC 
(p=0.001). The HPV IgG levels in the advanced 
stage (4,708±1,386) were significantly higher 
than in the early-stage (2,344±1,255) as 
shown in Table 3.
Discussion
Head and neck cancers are all cancers that 
originate in the upper aerodigestive tract, 
including the sinonasal tract, oral cavity, 
Table 1 Characteristics of Patients with Head and Neck Squamous Cell Carcinoma from 
 Dr. Hasan Sadikin General Hospital in 2019
Characteristics
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Note: * Fisher’s Exact test p<0,05.  ** Kolmogorov Smirnov test
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Table 2 Tumor Locations in Patients with Head and Neck Squamous Cell Carcinoma at 
 Dr. Hasan Sadikin Hospital in 2019
Tumor Locations
Clinical Stage













pharynx, or larynx. About 90% of head and 
neck cancers are squamous cell carcinomas. 
Cancers originates in the cells that line the 
mouth, nose, throat, ears, and also the surface 
of the tongue.1,8
Gender is a risk factor for head and neck 
cancer. HNSCC is more frequent in males than 
females, conform to the result in this study 
which showed that the male:female ratio of 
HNSCC patients was 2:1. This result is similar 
to a study in the Asia Pacific, which involved 
patients with HNSCC in various educational 
centers with a male:female ratio of 4:1.2 This 
might be related to exposure to cigarette 
smoke, alcohol, and carcinogenic. Moreover, 
patients with advanced stage are also mostly 
found in the male gender.2,9
Head and neck cancer is common in old 
age. Our initial search of medical records 
showed that of a total of 638 HNSCC patients, 
51.9% were from the 51–60 year age category 
and 23.8% were 60–70 years old. In our 
current study, patients >50 years were 75%, 
confirming that the patients of HNSCC mostly 
were at an average age of 57 years.10 This is 
caused by a long process of carcinogenesis. 
Due to the carcinogenesis process from 
normal tissue needs a long time. The highest 
prevalence of HNSCC is among tobacco users, 
of whom 74%  smoke >10 packs/year.5,10
According to the 2017 AJCC, HNSCC 
patients come at the advanced stage (III–IV) 
75%. The staging was designated based on 
the TNM scoring system namely tumor size, 
lymph nodes involvement, and metastasis. 
Only 25% of patients seek medical attention 
in the early stages (I–II). The main factors are 
difficulty in diagnosis, lack of symptoms, and 
lack of knowledge, besides the inadequate 
health facilities. The initial symptoms of head 
and neck tumors are typical, only resembling 
upper respiratory tract infections, stomatitis, 
voice changes, and nasal congestion.11
Human papillomavirus has been found in 
premalignant tumors and malignant tumors of 
the head and neck. Malignancy occurs due to 
HPV infection mediated by E6 and E7 proteins 
expression, inhibiting tumor suppressor 
gene pathways by inactivating TP53.12 The 
combined effect of the oncogeneous HVP, 
E6, E7, and E5 induces cell cycle progression 
in epithelial cells squamous oral cavity that 
is differentiated and growth suppressed, 
leading to carcinogenesis by proliferation 
deregulation, decreased apoptosis, genomic 
instability, and transformation processes. 
Measurement of several specific HPV16 
antibodies in serum up to 15 years before 
the diagnosis of oropharyngeal cancer has 
shown a correlation between baseline HPV16 
antibodies and antigens of E1, E2, E6, and E7 
in oropharyngeal cancer.12,13
In this study, the value of the HPV IgG level 
in the clinical stage of HNSCC Stage I–II and 
Stage III–IV were 2.1 and 4.9, respectively, 
suggesting a significant relationship (p=0.000) 
between the variable HPV IgG levels and both.
HPV infection in squamous cell epithelium 
causes the formation of specific antibody 
antigens. The antibodies formed are specific 
IgG against HPV.14 Examination of HPV 
IgG antibodies in OPSCC patients in this 
study found that 95.6% had detectable IgG 
antibodies, which can be used as predictor of 
Table 3 Comparison of HPV IgG Levels Based on Clinical Stage in Patients with Head and 
Neck Squamous Cell Carcinoma
Variable
Early Stage Advanced Stage
p-value












Note: **Unpaired T-test, p <0.05
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OPSCC risk. Specific HPV IgG antibodies serve 
as markers of squamous cell carcinogenesis 
and are important for strategies for the 
prevention or early detection of squamous cell 
carcinoma.7,15
The HPV serology was positively correlated 
with 86% of HNSCC patients who had been 
examined for HPV-DNA PCR and P16 IHC. The 
E7 antibody titer in serum was also positively 
correlated with p16 in HNSCC tissue, thus 
supporting the association between serological 
antibody and clinical stage with the incidence 
of HNSCC.10
Limitations in this study include the 
limited number of sample in the early-stages 
compared to the advanced stages. The HPV 
IgG examination has been detected by serum 
serology, measuring cumulative exposure of 
an individual to HPV infection. Thus, further 
research could be done to identify HNSCC 
caused by HPV using more sensitive and specific 
examination such as the combination of P16 
immunohistochemistry and PCRHPVDNA.
In conclusion, there is a correlation 
between increased levels of HPV IgG  and the 
clinical stage of HNSCC. Higher HPV IgG levels 
worsens the prognosis of HNSCC. Examination 
of HPV IgG levels can be used as a marker to 
assess the progression of HNSCC.
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